SGMT · XBRL financial data
Sagimet Biosciences financial statements, every fiscal year
The same tables from 5 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (SGMT's year ends in late December)
| In thousands of dollars | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|
| Revenue from contracts with customers | 2,000 | — | — |
| Research and development | 19,777 | 38,444 | 39,054 |
| General and administrative | 12,963 | 16,010 | 17,835 |
| Total operating expenses | 32,740 | 54,454 | 56,889 |
| Operating income (loss) | (30,740) | (54,454) | (56,889) |
| Other income (expense) | 2,864 | 8,887 | 5,851 |
| Income tax expense (benefit) | — | 0 | 0 |
| Net income (loss) | (27,876) | (45,567) | (51,038) |
| Earnings per share, basic USD per share | (2.66) | (1.45) | (1.58) |
| Earnings per share, diluted USD per share | (2.66) | (1.45) | (1.58) |
| Weighted average shares, basic thousands of shares | 10,460 | 31,351 | 32,346 |
| Weighted average shares, diluted thousands of shares | 10,460 | 31,351 | 32,346 |
Balance sheet
CSVFiscal years (SGMT's year ends in late December)
| In thousands of dollars | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|
| Cash and cash equivalents | 75,139 | 75,840 | 35,021 |
| Marketable securities | 19,758 | 75,410 | 78,103 |
| Marketable securities, non-current | — | 7,408 | 0 |
| Prepaid and other current assets | 1,749 | 1,524 | 3,280 |
| Total current assets | 96,646 | 152,774 | 116,404 |
| Right-of-use asset | 73 | 77 | 78 |
| Total assets | 96,719 | 160,259 | 116,482 |
| Accounts payable | 186 | 1,425 | 1,309 |
| Accrued liabilities | 5,403 | 2,951 | 3,714 |
| Total current liabilities | 5,654 | 4,454 | 5,101 |
| Lease liability, non-current | — | — | 0 |
| Total liabilities | 5,654 | 4,454 | 5,101 |
| Accumulated deficit | (249,744) | (295,311) | (346,349) |
| Total stockholders' equity | 91,065 | 155,805 | 111,381 |
| Total liabilities and equity | 96,719 | 160,259 | 116,482 |
| Common shares outstanding (cover page) thousands of shares | 0 | — | — |
Cash flows
CSVFiscal years (SGMT's year ends in late December)
| In thousands of dollars | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|
| Net income (loss) | (27,876) | (45,567) | (51,038) |
| Stock-based compensation | 4,990 | 5,288 | 6,449 |
| Net cash from operating activities | (23,766) | (42,435) | (45,650) |
| Net cash from investing activities | 12,580 | (61,683) | 4,556 |
| Proceeds from issuing common stock | — | 105,750 | 0 |
| Net cash from financing activities | 86,167 | 104,819 | 275 |
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Sagimet Biosciences | 165,896 | not reported | (11,099)* | not reported | 21.6 quarters | 10-QJun 30, 2026 |
| Aldeyra Therapeutics | 45,090 | not reported | (4,589)* | 60.3M | 9.8 quarters | 10-QJun 30, 2026 |
| Lifecore Biomedical | 23,035 | 25,322 | 6,946* | 37.9M | — | 10-QSep 30, 2026 |
| Heron Therapeutics | 20,721 | not reported | (2,213)* | 189.9M | 19.3 quarters | 10-QJun 30, 2026 |
| Precigen | 16,329 | 54,978 | (17,809)* | 358.0M | 2.1 quarters | 10-QJun 30, 2026 |
| SELLAS Life Sciences Group | 138,343 | not reported | (7,588)* | 201.9M | 18.2 quarters | 10-QJun 30, 2026 |
| Annexon | 199,270 | not reported | (48,007)* | not reported | 4.4 quarters | 10-QJun 30, 2026 |
| Perspective Therapeutics | 48,488 | not reported | (20,650)* | 114.2M | 11.5 quarters | 10-QJun 30, 2026 |
| Rocket Pharmaceuticals | 224,507 | 0 | (39,613)* | 109.8M | 7.2 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.